GLOW Peptide Blend

Key points

• Glow is a brand style name for a blend, usually GHK-Cu, BPC-157 and TB-500.
• It is marketed for skin and recovery.
• None of the components is licensed in the UK as an injectable medicine.
• The repair peptides are on the WADA Prohibited List.

Quick facts

What it is

Blend, usually GHK-Cu, BPC-157 and TB-500

Marketed for

Skin and recovery

UK status

Not a licensed medicine as an injectable; sold for research use

In sport

Repair peptide components prohibited

How it works

The blend brings together a copper peptide used in skincare with two peptides studied for tissue repair. Each is covered in its own entry, where the evidence and its limits are set out.

What the evidence shows

There is no evidence for Glow as a specific injectable product. The components have mostly animal or cosmetic evidence individually, and there are no human trials of the combination.

What it does not settle

• There are no human trials of this blend.
• The exact contents of a given vial are uncertain.
• Long term safety of the combination is unknown.

Side effects

Less common but serious

• The risks are those of the individual components, with the added uncertainty of what a blended product contains.
• Because there is no licensed injectable product, the dose, purity and contents of material bought online cannot be verified.

Report any suspected side effect through the MHRA Yellow Card scheme.

UK legal status and access

Glow, as an injectable blend, has no UK marketing authorisation, so it is not a licensed medicine and is not offered by registered clinics or pharmacies. It is sold online for research use. GHK-Cu used in topical skincare is a separate, legal cosmetic use.

Common questions